Quantity of suitable individuals: CDEC mentioned the uncertainty in the number of sufferers with reasonably severe to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some individuals who will be categorised as possessing mild or moderate disease may have a serious bleeding phe… Read More